Merck, Dynavax ink $136M deal on hep B therapy

Merck has agreed to put up $31.5 million as a down payment for the worldwide rights to Dynavax Technologies' late-stage hepatitis B therapy. Merck will also cover the remaining development cost on the drug, pay royalties and fork out up to $105 million in milestones. On Tuesday Dynavax reported that Hepislav hit its Phase III endpoint; protecting older adults as well as healthcare workers.

Merck already markets a hep B therapy, but appeared to be attracted by an easier dosing schedule for Hepislav and its ability to work on the weakened immune systems of older people. Hepislav combines a segment of the hepatitis B virus and a DNA sequence that activates a toll-like receptor, triggering an early immune response. A spokesperson for Dynavax told The New York Times that the potential market for the drug--which could hit the market in 2010--at around $500 million. Berkeley, CA-based Dynavax also has partnerships with AstraZeneca and the NIH.

- see this release
- check out the report from Hemscott

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.